As initial therapy in patients with HIV-1, treatment with abacavir-lamivudine may be less successful than treatment with tenofovir disoproxil fumarate-emtricitabine, according to a study published online Dec. 1 in the New England Journal of Medicine.
Dr. Ondo, clinical assistant professor of dermatology, University of New Mexico, Albuquerque, traveled 30 hours each way on a two-week journey to Hyderabad, near India's southeastern coast. He described the experience as interesting, memorable, and at times overwhelming.
The challenge of controlling HIV in patients with resistance to antiretrovirals has contributed to accelerated research into treatments with novel antiretroviral activity.